Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
Date:5/18/2011

SUNNYVALE, Calif., May 18, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that a clinical abstract on our Btk inhibitor, PCI-32765, has been selected for an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011 in Chicago, IL. Additionally, two clinical abstracts on PCI-32765 have been selected for oral presentations at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 15-18, 2011.

Pharmacyclics plans to present a material update on the PCI-32765 clinical development program in a press release after the ASCO oral presentation on Monday, June 6, 2011 and expects to hold a conference call as well. The update will encompass the entire PCI-32765 clinical development program and will specifically include: 1) safety and efficacy data with the use of single-agent PCI-32765 in relapsed/ refractory or treatment-naive chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL) in patients with adequate follow-up from our ongoing Phase IB/II trial, including patients with poor-risk disease; 2) an update of efficacy from the Phase 1A trial of PCI-32765 in B-cell malignancies, including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 3) a status update for ongoing PCI-32765 clinical studies, including  a pilot trial of PCI-32765 in the ABC subtype of diffuse large B-cell lymphoma, a phase II trial of single agent PCI-32765 in mantle cell lymphoma, and studies with PCI-32765 in combination with either bendamustine/rituximab (BR), fludarabine/cyclophosphamide/rituximab (FCR), or ofatumumab in CLL. Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)Abstract #6508Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PMSession Title: Leukemia, Myelodysplasia and TransplantationLocation: Arie Crown TheaterOral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)Abstract # 122Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study.  S. O'Brien et al. Date/Time: Friday, June 17, 2011; 9:45 AMSession 10: Chronic Lymphocytic Leukemia (CLL)Location: Room A, B, C and Marquee Parco Ciani)Abstract # 153Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study.  R.H. Advani et al.Date/Time: Saturday, June 18, 2011; 9:30 AMSession 14:  Signaling Pathways in LymphomaLocation: Room AAbout PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
2. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
3. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
4. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
5. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
6. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
7. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
8. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
9. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
10. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):